Low-level laser therapy in the prevention and treatment of chemotherapy-induced oral mucositis in young patients
Photomedicine and Laser SurgeryVolume 26, Number 4, 2008 Mary Ann Liebert, Inc. Pp. 393–400DOI: 10.1089/pho.2007.2144
Low-Level Laser Therapy in the Prevention and Treatment
of Chemotherapy-Induced Oral Mucositis in Young Patients
Meire Maman Fracher Abramoff, D.D.S.,6 Nilza Nelly Fontana Lopes, D.D.S., M.S.,1
Luciana Almeida Lopes, D.D.S., M.S., Ph.D.,2 Luciano Lauria Dib, D.D.S., M.S., Ph.D.,3
Arnaldo Guilherme, M.D., Ph.D.,4 Eliana Monteiro Caran, M.D., Ph.D.,1 Adriana Delboni Barreto, D.D.S.,6
Maria Lucia Martinho Lee, M.D.,5 and Antônio Sérgio Petrilli, M.D., Ph.D.1
Abstract Objective: A pilot clinical study was conducted to evaluate the efficacy and feasibility of low-level laser ther- apy (LLLT) in the prevention and treatment of chemotherapy (CT)-induced oral mucositis (OM) in young pa- tients. Background Data: Besides compromising the patient’s nutrition and well-being, oral mucositis represents a portal of entry into the body for microorganisms present in the mouth, which may lead to sepsis if there is hematological involvement. Oncologic treatment tolerance decreases and systemic complications may arise that interfere with the success of cancer treatment. LLLT appears to be an interesting alternative to other approaches to treating OM, due to its trophic, anti-inflammatory, and analgesic properties. Materials and Methods: Patients undergoing chemotherapy (22 cycles) without mucositis were randomized into a group receiving prophylactic laser-irradiation (group 1), and a group receiving placebo light treatment (group 2). Patients who had already presented with mucositis were placed in a group receiving irradiation for therapeutic purposes (group 3, with 10 cycles of CT). Serum granulocyte levels were taken and compared to the progression of mucositis. Results: In group 1, most patients (73%) presented with mucositis of grade 0 (p ϭ 0.03 when compared with the placebo group), and 18% presented with grade 1. In group 2, 27% had no OM and did not require therapy. In group 3, the patients had marked pain relief (as assessed by a visual analogue scale), and a decrease in the severity of OM, even when they had severe granulocytopenia. Conclusion: The ease of use of LLLT, high patient acceptance, and the positive results achieved, make this ther- apy feasible for the prevention and treatment of OM in young patients. Introduction
The estimated incidence of oral complications4 varies with
the type of therapy patients undergo, but occurs in approx-
PATIENTS WHO UNDERGO CHEMOTHERAPY (CT) and radio- imately 40% of patients receiving chemotherapy, 80% those
therapy (RT) for the treatment of malignant neoplasia of-
receiving bone marrow transplants, and 100% of patients re-
ten present with oral mucositis (OM) as a side effect. This
ceiving radiotherapy of the head and neck, if the oral cavity
stomatotoxicity strongly impacts the quality of life of these
is in the irradiated field. Younger patients have a higher in-
individuals, with higher morbidity and mortality rates and
cidence of oral complications5 than older patients receiving
length of hospital stay, that lead to higher costs of treatment.1
Thus from the patient’s point of view, OM is the most de-
CT’s cytotoxic action on the epithelial basal cell layer leads
bilitating complication accompanying a bone marrow trans-
to a decrease in the renewal rate of these cells, with atrophy
and ulceration of the tissues. These drugs simultaneously at-
1Pediatric Oncology, Institute IOP GRAACC/UNIFESP, Federal University of São Paulo, 2Research and Education Center for Photo
Therapy in Health Sciences (NUPEN), 3Stomatology, Paulista University (UNIP), 4Otorhinolaryngology and Head and Neck Surgery,UNIFESP, Federal University of São Paulo, 5Pediatric Institute (IOP/GRAACC/UNIFESP), Federal University of São Paulo, and 6Privatepractice, São Paulo, Brazil. ABRAMOFF ET AL.
tack the bone marrow, inducing granulocytopenia and
posed to demonstrate these beneficial effects for the pre-
thrombocytopenia, and predisposing the patient to infec-
vention and treatment of OM in oncologic patients,43–54 but
tions and bleeding.6 The ulcerated oral epithelium allows en-
comparisons are difficult due to the lack of standardization
try into the body of the oral microbiota, and may cause lo-
cal and systemic infections. With the oral pain they suffer,
OM is a result of various etiological agents and has char-
patients tend to become dehydrated and malnourished.
acteristics that change as it progresses. LLLT acts in a bene-
The cellular and molecular changes seen as mucositis pro-
ficial and non-invasive way, producing no collateral effects.
gresses7 occur soon after the administration of RT or CT, and
Based on the accumulated evidence, the Multinational As-
lead to DNA strand breakage and the liberation of reactive
sociation of Supportive Care in Cancer and the International
oxygen species (ROS). The ROS activate transcription factors
Society for Oral Oncology (MASCC/ISOO)55,56 suggest the use
such as P-53 and nuclear factor-B,8 leading to cell death.
of LLLT for OM prevention in hematopoietic stem cell trans-
These transcription factors also induce liberation of cyto-
plant patients. Nevertheless, no guidelines have been estab-
kines, such as tumor necrosis factor-␣, interleukin-11␤, and
lished and further studies should be well designed. The aim
interleukin-6, which are responsible for alterations in the
of this clinical pilot study is to evaluate the efficacy and feasi-
connective tissue9 and endothelium,10 with consequent dam-
bility of LLLT in the prevention and treatment of OM in young
age to the basal layer of the epithelium. The healing of non-
patients who are undergoing high-dose chemotherapy.
infected mucositis occurs in a physiological way, and is as-sociated with decreases in drug toxicity and re-establishment
Materials and Methods
of the granulocyte count,7,11 which favor the healing process. These biological events are influenced by various factors,
such as drug toxicity, dose, the interval between cycles, as-
This prospective, randomized, placebo-controlled study
sociated radiotherapy, the general health of the patient, sus-
was approved by the Ethics Committee and developed for
ceptibility to the CT agents, and patient dental condition and
outpatients of the Pediatric Oncology Institute (GRAACC)
of São Paulo Federal University between February and Au-
There is a wide range of procedures and products to alle-
gust 2003. All patients or their parents or guardians signed
viate the effects of oral mucositis, such as antimicrobial
rinses, mucosa protectants, cryotherapy, topical analgesics,
A total of 13 patients were included, with a total of 32 CT
and more recently the use of keratinocyte growth factor-112
cycles, of which 21 cycles were for osteosarcoma treatment,
and phototherapy such as low-level laser therapy (LLLT).
and 11 cycles were for high-risk acute lymphoid leukemia
The mechanism behind the laser’s interactions with bio-
(ALL) treatment. There were 5 males and 8 females and their
logical tissues is only partly understood, but it is described
mean age was 14.6 y (range 7–23 y).
as a photobiological phenomenon in which primary pho-
The CT regimens of the osteosarcoma patients are sum-
toacceptors (chromophores) such as cytochrome c oxidase,
marized in Table 1. The patients who underwent ALL treat-
flavins, and porphyrins, absorb certain wavelengths, caus-
ment received CT in accordance with the criteria of the
ing a cascade effect in the respiratory chain, which results in
Brazilian Group for the Treatment of Leukemia in Childhood
the production of energy to fuel cell metabolic processes.13,14
LLLT’s photostimulation of biological tissues depends on
Patients with unstable clinical condition, severe oral in-
the use of the proper parameters, and this is still under in-
fections, and those with head and neck malignancies were
vestigation, but since the 1960s15,16 there has been strong ev-
idence indicating the potential of LLLT to hasten healing. Laser therapy enhances microcirculation,17–20 improves lym-
phatic drainage,21–23 promotes pain relief,24–29 and increasesproliferation and mobility of epithelial cells.16,30–32 There are
Standardized methods of oral hygiene were established
also significant increases in fibroblast production and activ-
with the use of soft toothbrushes and mouth rinsing with bi-
ity,33–38 which accelerate collagen synthesis.39–42
carbonate solution four times a day. Adequate oral intake
Our improved understanding of the pathophysiology of
was achieved before CT to avoid trauma and to reduce the
OM has made possible the introduction of new approaches
to treat the manifestations of stomatotoxicity. Recently pub-
Patients without OM when they begun CT were random-
lished studies have demonstrated the wide range of benefits
ized into group 1 (prophylactic laser irradiation) or group 2
of LLLT for biological tissues. Several trials have been pro-
TABLE 1. CHEMOTHERAPY PROTOCOL FOR THE PATIENTS WITH OSTEOSARCOMA
LLLT IN THE MANAGEMENT OF CHEMOTHERAPY-INDUCED ORAL MUCOSITIS High-risk
and/or peripheral blasts in D14and/or BM M2/M3 in D28
Remission Remission induction induction M1 / M2 / M3 Intensification Late consolidation Maintenance
The chemotherapy protocols of the patients with high-risk ALL. BM, bone marrow; BMT, bone marrow trans-
plantation; MTX, methotrexate; DEXA, dexamethasone; VCR, vincristine; L-ASP, L-asparaginase; DAUNO, daunorubicin;6-TG, 6-thioguanine; CYCLO, cyclophosphamide; 6-MP, 6-mercaptopurine; ARA-C, cytarabine; VP-16, etoposide; IFO, ifos-famide; MADIT, methotrexate ϩ ARA-C ϩ dexamethasone intrathecal.
Patients presenting with OM at their first examination
tis, between the sixth and ninth days after beginning CT. The
were placed in group 3 (therapeutic laser irradiation).
patients in both groups were blinded as to whether they re-
The beginning of each CT cycle was considered a new case
and the patients were subjected to new randomization. The prophylactic laser group and the placebo laser group
The first laser irradiation session was done as soon as mu-
The first irradiation was performed within 24 hours of be-
cositis was diagnosed, and the two following sessions were
ginning CT, and the next two irradiations were performed
every other day. The third one corresponded with the be-
The clinical evaluations were conducted prior to irradia-
ginning of the period of highest risk of developing mucosi-
tion. After a total of three laser therapy sessions, patients
ABRAMOFF ET AL.
TABLE 2. CHANGES IN MUCOSITIS GRADE IN PATIENTS
Pain scored from 1–4 was considered mild, that scored from
4.1–7 was moderate, and scores Ն7 were considered intense.
In the presence of infections caused by fungi, bacteria, or
viruses, a therapeutic regimen was established, and the eval-
uation of laser effectiveness was restricted to signs and
symptoms of OM lesions, without consideration as to
whether the laser therapy could cure the infection.
Granulocyte levels were evaluated because they behave
similarly to the epithelial cells of the oral mucosa when ex-
posed to CT agents. The granulocyte levels were classified
one of three ways: Ն2000/mm3, from 1000–2000/mm3, and
Ͻ1000/mm3. Filgrastim use was also considered because itraises serum granulocyte levels.
who did not present with mucositis were excluded from the
protocol. If mucositis persisted, more laser sessions werescheduled.
The mucositis grades and granulocyte levels were com-
pared at the first and third evaluation. Then the mucositis
grades of the prophylactic laser group were compared withthose of the placebo laser group.
An AsGaAl diode laser was used (THERA LASER; DMC
The results were analyzed using the comparison test for
Equipments Ltda. São Carlos, Brazil) operating at 685 nm,
two proportions, which is a non- parametric qualitative test.
35 mW output power, continuous wave, and a 600-m spot.
The value considered statistically significant was p Ͻ 0.05.
The energy delivered was 2 J per point of application, andthe fluence was approximately 72 J/cm2. The time spent at
each point was 54 sec. Laser energy was application punc-tually, perpendicular to the tissue. The tip of the laser was
disinfected with 70% alcohol solution and wrapped with a
There were seven patients in this group, with a total of 11
plastic film. Patients and operators wore glasses for eye pro-
CT cycles. All patients were undergoing osteosarcoma treat-
The following areas were irradiated: the left and right ju-
In the third evaluation, among the 8 patients without mu-
gal mucosa (two points on each side), the superior and in-
cositis (Table 2), there were 5 cases with granulocyte levels
ferior internal lip mucosa (one point in each quadrant), the
Ͻ2000/mm3 (Table 3). It must be emphasized that two pa-
floor of the mouth (one point on each side), the lateral edge
tients with granulocyte levels Ͼ2000/mm3 had taken fil-
of the tongue (two points on each side), the tip of the tongue
(one point), the smooth palate (one point on each side), and
In the second evaluation, candidiasis was diagnosed in the
patient who presented with grade II mucositis. Once the in-fection treatment regimen was established, laser application
was performed and this patient reported pain reduction from
Patients were clinically evaluated with regard to OM
severity, painful symptomatology, esophagitis, and they
In the second evaluation, esophagitis was observed in just
were asked if they used filgrastim (Granulokine®). The
one patient. This patient reported intense pain in the phar-
changes in granulocyte levels were evaluated through hema-
ynx (grade 9), but for the oral-cavity mucositis the grade was
0, and granulocyte levels were Ͻ1000/mm3. In the third eval-
Oral mucosal toxicity and esophagitis were graded ac-
uation, three patients presented with esophagitis, but did not
cording to the National Cancer Institute’s Common Toxicity
present with mucositis in the oral cavity.
Criteria, version 2.0.57 Pain was evaluated before and after
All patients progressed toward the resolution of OM with
laser application via a visual analog scale scored from 0–10.58
TABLE 3. CHANGES IN GRANULOCYTE LEVELS IN PATIENTS
LLLT IN THE MANAGEMENT OF CHEMOTHERAPY-INDUCED ORAL MUCOSITIS
TABLE 4. CHANGES IN MUCOSITIS GRADE IN PATIENTS
cles were for ALL. These patients had already shown some
degree of mucositis at the first evaluation. This group hadCT beginning on the date of the first examination, and con-
tinued it for 1–7 d, with an average of 3 d.
At the first evaluation of the protocol, seven episodes of
pain were noted, two of them (29%) mild pain, and five (71%)
moderate pain. At the second evaluation, after one laser ses-sion, five reported (71%) episodes of mild pain, and two
(29%) episodes of moderate pain. At the third evaluation, of
the 10 CT cycles evaluated, only three (30%) cases of mild
pain were noted; however, these patients were able to speak
and eat in spite of the pain. At the third evaluation only oneoccurrence of moderate pain was noted, and after anotherlaser session it became mild.
At the third evaluation, most patients regardless of their
low granulocyte levels (80% of patients), did not have severemucositis (Table 6), and they could eat and continue their
Seven patients were evaluated, having a total of 11 CT cy-
cles. Among them, 5 cycles were for osteosarcoma treatment,
Also at the third evaluation, among the six patients with
and 6 cycles were for ALL treatment.
granulocyte levels Ͻ1000/mm3 (Table 7), two of them pre-
Some patients (3) presented with grade I mucositis at the
sented with grade 0 mucositis, one patient had OM grade I,
first examination, but they were randomized into this group
and three patients had OM grade II. The patients with grade
because they had mild edema in the jugal mucosa. All these
II OM had grade III OM at the previous evaluations, and
patients maintained grade I mucositis during all three eval-
they improved after LLLT in spite of granulocytopenia. OM
healing occurred in all of them, with no need for further
In this group mucositis episodes were frequent (Table 4),
but they were not as severe, because when grade II mucosi-tis was diagnosed, therapeutic measures had already been
established. Also, these patients were under supervision,which may have promoted better oral hygiene, which is
LLLT was well tolerated, even when patients presented
known to decrease the severity of OM.
with severe lesions, which makes this therapy tolerable to
The levels of granulocytes in the placebo group did not
children. There were no patients who discontinued LLLT be-
cause they found it to be unacceptable. With the improve-
At the first evaluation, no patients reported pain, while at
ment in signs and symptoms, some patients did not attend
the third evaluation three patients mentioned pain in the oral
the following sessions, which made follow-up of these pa-
cavity. Two patients had viral infections at the third evalu-
ation, and therapeutic intervention was necessary in three
Several patients repeated the CT cycles with similar drugs
and dosages, and were randomized once again within theLLLT protocol. This procedure allowed the comparison of
Placebo versus prophylactic laser group
different approaches to treating OM in the same patient, orin those with similar CT protocols.
At the third evaluation, 73% of the patients in the pro-
For instance, two patients with the same disease and sim-
phylactic laser group did not have mucositis, and in the
ilar CT regimens (high-dose methotrexate) were included in
placebo group 27% had no mucositis, a difference that
the prophylactic laser group, and later, because at the first
reached statistical significance (p ϭ 0.03).
examination they had already presented with signs of OM,they were included in the therapeutic laser group. When they
were prophylactically irradiated they had mucositis grade 0
Six patients (10 CT cycles in all) were followed-up. Five
or I at the three evaluations. On the other hand, when the
cycles were given for osteosarcoma treatment, and five cy-
therapeutic laser protocol was used, they developed mu-
TABLE 5. CHANGES IN GRANULOCYTE COUNT IN PATIENTS
ABRAMOFF ET AL.
TABLE 6. CHANGES IN MUCOSITIS GRADE IN PATIENTS
tablishment of conditions that favor healing occurs. We ob-
served a decrease in the intensity of OM, even in those withsevere granulocytopenia.
The difficulty of demonstrating the laser’s efficacy in on-
cologic patients with OM results from the variety of disease
types and chemotherapy and radiotherapy protocols. There
is also a lack of a consistent classification system to evaluatethe severity of OM, and the possibility of spontaneous heal-
ing in many cases without complications. As CT agents have
different toxicity levels, the short interval between CT cycles
makes it difficult to determine which drugs may intensify
Also, it was difficult to determine the appropriate laser pa-
rameters to use in pediatric patients. The energy levels usedhere were based on several small pilot studies performed by
cositis grade III at the second evaluation, and mucositis
our group. From an initial energy level of approximately 1
J, we evaluated clinical responses with levels up to 3 J. We
It was also possible to compare three CT cycles with high-
found 2 J to be a good compromise between the results ob-
dose methotrexate in a patient. We noted remarkable results:
tained and the time spent on laser application.
in the first two cycles with prophylactic laser irradiations,
The reduction in OM-induced pain was the most remark-
the patient presented mucositis grades 0 and I. In the third
able effect reported by our patients, a fact in agreement with
cycle, this patient was randomized to the placebo group data found in the literature.43–45,47,51,53,54 This prompt alle-and mucositis grade III was diagnosed, and required addi-
viation allowed patients to improve their nourishment,
which improved their overall state of health.
Methotrexate (MTX) and cytarabine (ARA-C) are an-
The ease of use of LLLT, the ability to treat OM in a few
timetabolite cell-cycle-phase specific drugs with significant
irradiation sessions, the low cost of the equipment, the high
cytotoxic potential for the oral and gastric mucosa. In the
patient satisfaction with the protocol, and the successful re-
protocol for ALL treatment these agents were administrated
sults obtained in this study, make this therapy feasible for
simultaneously or over a short time interval. For osteosar-
the prevention and treatment of OM in pediatric patients.
coma treatment, the recommended dose of MTX was 12g/m2, as an alternative therapy regimen for patients with re-
In spite of our small patient sample, it is worth noting that
The use of LLLT for prophylactic purposes showed the
most did not develop OM when prophylactically irradiated,
most satisfactory outcomes, a fact in accordance with data
and there was quick recovery and pain relief for those in the
found in the literature.43–46,48–50,52–54 For therapeutic appli-
therapeutic laser group, even in those with significant gran-
cations, the patients noted pain relief, and there were no re-
ulocytopenia, thus enabling them to better tolerate their che-
ports of OM worsening after LLLT, even when the granulo-
motherapy regimens. This demonstrates that LLLT has both
a preventive and a therapeutic role in those prone to develop
Some authors also demonstrated that light-emitting
OM. Further clinical studies are needed with greater num-
diodes are helpful in treating OM.59,60 Their effects similar
bers of patients to optimize the laser parameters, to test
to those of LLLT are explained by the fact the coherence of
LLLT’s effectiveness with various CT regimens, and to fur-
laser light is lost in the top layers of biological tissues, and
ther explore this treatment option for OM, which could
thus the photo-stimulatory effects are more related to the
light’s parameters than to the light source employed.61
In the present study, the comparison of the evolution of
mucositis with the granulocyte count allowed differentiationof beneficial laser effects from those of the physiologic evo-
We want to thank all of the patients and their families.
lution of OM. Also, when drug toxicity is reduced, the re-es-
Thanks also to Armando Reis Tavares, Jimmy Adans, Maria
TABLE 7. CHANGES IN GRANULOCYTE LEVELS IN PATIENTS
LLLT IN THE MANAGEMENT OF CHEMOTHERAPY-INDUCED ORAL MUCOSITIS
Cristina Iglesias, and Ricardo B. Iannuzzi for assistance in
duced spasm in atherosclerotic Yucatan micro-suine. Circu-
manuscript preparation. We also thank Mr. Renaldo
Mansini, Jr. of DMC Equipmentos Ltda., São Carlos, Brazil,
19. Maegawa, Y., Itoh, T., Hosokawa, T. et al. (2000). Effects of
for the aid with the laser equipment.
near-infrared low-level laser irradiation on microcirculation. Lasers Surg. Med. 27, 427–437.
20. Ihsan, M.F.R. (2005). Low-level laser therapy accelerates col-
lateral circulation and enhances microcirculation. Pho-
1. Sonis, S.T., Oster, G., Fuchs, H., et al. (2001). Oral mucositis
and the clinical and economic outcomes of hematopoietic
21. Lievens, P. (1988). Effects of laser treatment on the lymphatic
stem cell transplantation. J. Clin. Oncol. 19, 2201–2205.
system and wound healing. LASER. J. Eur. Med. Laser Ass.
2. Bellm, L.A., Epstein, J.B., Rose-Ped, A., et al. (2000). Patients
reports of complications of bone marrow transplantation.
22. Lievens, P.C. (1991). The effect of IR laser irradiation on the
vasomotricity of the lymphatic system. Laser Med. Sci. 6,
3. Cheng, K.K.-F. (2007). Oral mucositis, dysfunction, and dis-
tress in patients undergoing cancer therapy. J Clin. Nursing.
23. Almeida Lopes, L., and Lopes, A. (2006). Técnica da
OnlineEarly Articles. Available at: http://www.blackwell-
Drenagem Linfática Ativada por Laserterapia, in: Atualiza-
ção Clínica em Odontologia. L.L. Dib, and M.S. Saddy, (eds.).
4. National Cancer Institute. (2004). Oral complication of che-
São Paulo: Editora Artes Médicas v.1, pp. 327–340.
motherapy and head/neck radiation PDQ, pp. 1–49. Avail-
24. Colls, J. (1986). La terapia laser, hoy. Barcelona: Centro Doc-
able at: http://www.cancer.gov/cancertopics/pdq/sup-
25. Ataka, I., Kazuhiro, K., Kenji, Y., et al. (1989). Studies of
5. Sonis, S.T., Sonis, A.L., and Lieberman, A. (1978). Oral com-
Nd:YAG low power laser irradiation on stellate ganglion,
plications in patients receiving treatment for malignancy
in: Lasers in Dentistry. H. Yamamoto, K. Atsumi, and H.
other than head and neck. J. Am. Dent. Assoc. 97, 468–472.
Kusakari, (eds.). Amsterdam: Elsevier, pp. 271–276.
6. Lockhart, P.B., and Sonis, S.T. (1979). Relationship of oral
26. Honmura, A., Ishii, A., Yanase, M., et al. (1993). Analgesic
complications to peripheral blood leukocyte and platelet
effect of Ga-Al-As diode laser irradiation on hyperalgesia in
counts in patients receiving cancer chemotherapy. Oral Surg.
carrageenan-induced inflammation. Lasers Surg. Med. 13,
7. Sonis, S.T. (2004). The pathobiology of mucositis. Nat. Rev.
27. Laakso, E., and Cabot, P.J. (2005). Nociceptive scores and en-
dorphin-containing cells reduced by low-level laser therapy
8. Sonis, S.T. (2002). The biologic role of nuclear factor-B in
(LLLT) in inflamed paws of Wistar rat. Photomed. Laser
disease and its potential involvement in mucosal injury as-
sociated with antineoplastic therapy. Crit. Rev. Oral Biol.
28. Ferreira, D.M., Zângaro, R.A., Balbin Villaverde, A., et al.
(2005). Analgesic effect of He-Ne (632.8 nm) low-level laser
9. Sonis, S.T., Peterson, R.L., Edwards, L.J., et al. (2000). Defin-
therapy on acute inflammatory pain. Photomed. Laser Surg.
ing mechanisms of action of interleukin-11 on the progres-
sion of radiation induced oral mucositis in hamsters. Oral
29. Bjordal, M.J., Johnson, M.I., Iversen, V., et al. (2006). Low-level
laser therapy in acute pain: A systematic review of possible
10. Paris, F., Fuks, Z., Kang, A., et al. (2001). Endothelial apop-
mechanisms of action and clinical effects in randomized
tosis as the primary lesion initiating intestinal radiation
placebo-controlled trials. Photomed Laser Surg. 24, 158–168.
damage in mice. Science. 293, 293–297.
30. Enwemeka, C.S. (1988). Laser biostimulation of healing
11. McCarty, G.M., Awde, J.D., Ghandi, H., et al. (1998). Risk
wounds: specific effects and mechanism on action. J. Orthop.
factors associated with mucositis in cancer patients receiv-
ing 5- fluorouracil. Oral Oncol. 34, 484–490.
31. Steinlechner, C.W.B., and Dyson, M. (1993). The effects of
12. Spielberger, R., Stiff, P., Bensinger, W., et al. (2004). Palifer-
low level laser therapy on the proliferation of keratinocytes.
min for oral mucositis after intensive therapy for hemato-
logic cancers. N. Engl. J. Med. 351, 2590–2598.
32. Mognato, M., Squizzato, F., Facchin, F., et al. (2004). Cell
13. Karu, T., Ryabykh, T.P., Fedoseyeva, G.E., et al. (1989). He-
growth modulation of human cells irradiated in vitro with
lium-neon laser-induced respiratory burst of phagocyte
low-level laser therapy. Photomed Laser Surg. 22, 523–526.
cells. Lasers Surg. Med. 9, 585–588.
33. Enwemeka, C.S. (1992). Ultrastructural morphometry of
14. Karu, T. (1999). Primary and secondary mechanisms of ac-
membrane-bound intracytoplasmatic collagen fibrils in ten-
tion of visible to near-IR radiation on cells. J. Photochem.
don fibroblasts exposed to He-Ne laser beam. Tissue Cell.
15. Mester, E., Ludany, M., Sellyei, M., et al. (1968). The stimu-
34. Lubart, R., Friedmann, H., Sinykov, M., et al. (1995). Bios-
lating effect of low power laser ray on biological systems.
timulation of photosensitized fibroblasts by low incident
levels of visible light energy. Laser Ther. 7, 101–106.
16. Mester, A.F., and Snow, J.B. (1990). Photochemical effects of
35. Almeida-Lopes, L., Rigau, J., Jaeger, M.M.M., et al. (1998).
low-intensity laser irradiation on wound healing and on the
Acción del láser a baja densidad de potencia en la prolif-
maturation and regeneration of olfactory neuroepithelial ex-
eración in vitro de fibroblastos de procedencia humana. Bol.
plants. J. Clinical Laser Med. Surg. 8, 31–33.
17. Miró, L., Coupe, M., Charras, C., et al. (1984). Estudio capi-
36. Almeida-Lopes, L., Rigau, J., Zângaro, R.A., Guidugli-Neto,
loroscópico de la acción de un láser de AsGa sobre la mi-
J., and Marques Jaeger, M.M. (2001). Comparison of the low
crocirculación. Inv. Clin. Laser 1, 9–14.
level laser therapy effects on cultured human gingival fi-
18. Gal, D., Chokshi, S.K., Mosseri, M., et al. (1992). Percuta-
broblasts proliferation using different irradiance and same
neous delivery of low laser energy reverses histamine-in-
fluence. Lasers Surg. Med. 29, 179–184. ABRAMOFF ET AL.
37. Almeida-Lopes, L. (2003). Análise in vitro da Proliferação
51. Nes, A.G., and Posso, M.B.S. (2005). Patients with moderate
Celular de Fibroblastos de Gengiva Humana Tratados com
chemotherapy-induced mucositis: pain therapy using low
Laser de Baixa Intensidade Utilizando Diferentes Parâmet-
intensity lasers. Int. Nurs. Rev. 52, 68–72.
ros de Irradiação [Ph.D. thesis for degree in materials engi-
52. Antunes, H.S., de Azevedo, A.M., da Silva Bouzas, L.F., et
neering, in Portuguese]. Interunidades IFSC/IQSC/EESC,
al. (2007). Low-power laser in the prevention of induced oral
São Paulo University, São Carlos, Brazil.
mucositis in bone marrow transplantation patients: a ran-
38. Hawkins, D., and Abrahamse, H. (2006). Effect of multiple
domized trial. Blood. 109, 2250–2255.
exposures of low-level laser therapy on the cellular re-
53. Jaguar, G.C., Prado, J.D., Nishimoto, I.N., et al. (2007). Low-
sponses of wounded human skin fibroblasts. Photomed
energy laser therapy for prevention of oral mucositis in he-
matopoietic stem cell transplantation. Oral Dis. (OnlineEarly
39. Enwemeka, C.S., Rodriguez, O., Gall, N.G., et al. (1990). Mor-
Articles). Available at: http://www.blackwell-synergy.
phometrics of collagen fibril populations in He-Ne laser pho-
tostimulated tendons. J. Clin. Laser Med. Surg. 8, 151–156.
54. Schubert, M.M., Eduardo, F.P., Guthrie, K.A., et al. (2007).
40. Skinner, S.M., Gage, J.P., Wilce, P.A., et al. (1996). A pre-
A phase III randomized double-blind placebo-controlled
liminary study of the effects of laser irradiation on collagen
clinical trial to determine the efficacy of low level laser ther-
metabolism in cell culture. Aust. Dent. J. 41, 188–192.
apy for the prevention of oral mucositis in patients under-
41. Reddy, G.K., Stehno-Bittel, L., and Enwemeka, C.S. (2001).
going hematopoietic cell transplantation. Support. Care
Laser photostimulation accelerates wound healing in dia-
Cancer (Online First). Available in: http://www.springer-
betic rats. Wound Repair Regen. 9, 248–255.
42. Pereira, A.N., Eduardo, C.P., Matson, E., et al. (2002). Effect
55. Rubenstein, E.B., Peterson, D.E., Schubert, M., et al. (2004).
of low-power laser irradiation on cell growth and procolla-
Clinical practice guidelines for the prevention and treatment
gen synthesis of cultured fibroblasts. Lasers Surg. Med. 31,
of cancer therapy-induced oral and gastrointestinal mucosi-
43. Ciais, G., Namer, M., Schneider, M., et al. (1992). La
56. Keefe, D.M., Schubert, M.M., Elting, L.S., et al. (2007). Up-
laserthérapie dans la prévention et le traitement des mucites
dated clinical practice guidelines for the prevention and
liées á la chimiothérapie anticancéreuse. Bull. Cancer 79,
treatment of mucositis. Wiley InterScience. Available at:
44. Barasch, A., Peterson, D.E., Tanzer, J.M., et al. (1995). He-
lium-neon laser effects on conditioning-induced oral mu-
57. Cancer Therapy Evaluation Program. (1998). Common
cositis in bone marrow transplantation patients. Cancer. 76,
Toxicity Criteria Version 2.0. DCTD, NCI, NIH, DHHS.
Available at: http://ctep.cancer.gov/forms/CTCv20_4-30-
45. Cowen, D., Tardieu, C., Schubert, M., et al. (1997). Low en-
ergy helium-neon laser in the prevention of oral mucositis
58. McGrath, P.J., Beyer, J., Cleeland, C., et al. (1990). Report of
in patients undergoing bone marrow transplant: results of a
the subcommittee on assessment and methodologic issues
double blind randomized trial. Int. J. Radiat. Oncol. Biol.
in the management of pain in childhood cancer. Pediatrics.
46. Bensadoun, R.J., Franquim, J.C., Ciais, G., et al. (1999). Low-
59. Whelan, H.T., Connelly, J.F., Hodgson, B.D., et al. (2002).
energy He/Ne laser in the prevention of radiation-induced
NASA light-emitting diodes for the prevention of oral mu-
mucositis. A multicenter phase III randomized study in pa-
cositis in pediatric bone marrow transplant patients. J Clin.
tients with head and neck cancer. Support Care Cancer. 7,
60. Corti, L., Chiarion-Sileni, V., and Aversa, S. (2006). Treat-
47. Migliorati, C., Massumoto, C., de Paula Eduardo, F., et al.
ment of chemotherapy-induced oral mucositis with light-
(2001). Low-energy laser therapy in oral mucositis. J. Oral
emitting diode. Photomed. Laser Surg. 24, 207–213.
61. Karu, T.J., Tiphlova, O.A., Letokhov, V.S., et al. (1983). Stim-
48. Wong, S.F., and Wilder-Smith, P. (2002). Pilot study of laser
ulation of E. coli growth by laser and incoherent red light.
effects on oral mucositis in patients receiving chemotherapy.
49. Sandoval, R.L., Koga, D.H., Buloto, L.S., et al. (2003). Man-
agement of chemo and radiotherapy induced oral mucosi-
Dr. Meire Maman Fracher Abramoff, D.D.S.
tis with low-energy laser: initial results of A.C. Camargo
Hospital. J. Appl. Oral Sci. 11, 337–341.
50. Genot, M.T., and Klastersky, J. (2005). Low-level laser for
prevention and therapy of oral mucositis induced by che-motherapy or radiotherapy. Curr. Opin. Oncol. 17, 236–240.
MEN has many complications and diseases associated with it. Zollinger-Ellison Syndrome (ZES) is relatively common to people with MEN 1. The syndrome was first described by the Norwegian doctor Roar Strøm in 1952. Therefore the syndrome sometimes also is called Strøm-Zollinger–Ellison syndrome in the literature. The syndrome was later described in 1955 by Robert Zollinger and Edwin Ellison,
When is the Birthday of Christ? Examining the Historical and Biblical Evidence for the Time of Messiah's Birth Written by David M Rogers www.BibleTruth.cc Published: 2004 Table of Contents In the Western world, the single most popular and dearly loved of all holidays is Christmas. With "chestnuts roasting on an open fire" and "Jingle Bells," no other ho